Philip James Saylor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Philip James Saylor has a total of 173 co-authors. Here are the top co-authors by number of shared publications:
- David Brian Sykes
Massachusetts General Hospital, Boston, MA
19 shared publications - Shenglin Mei
Center for Regenerative Medicine, Massachusetts General Hospital, Boston, USA
19 shared publications - Ninib Baryawno
Division of Pediatric Oncology and Pediatric Surgery, Department of Women’s and Children’s Health, Karolinska Institutet, Stockholm, Sweden
18 shared publications - Taghreed Hirz
Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts
17 shared publications - Chin-Lee Wu
Department of Pathology, Harvard Medical School, Massachusetts General Hospital, Boston, MA
16 shared publications - Shulin Wu
Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
16 shared publications
Latest Publications
- 15 October 2025
- Published by Elsevier in The Spine Journal
- Vol. 26 (4) , 806-820
Efficacy of bone-modifying agents in preventing vertebral complications of multiple myeloma: a systematic review and meta-analysis
- 15 October 2025
- Published by Elsevier in The Spine Journal
- Vol. 26 (4) , 806-820
Efficacy of bone-modifying agents in preventing vertebral complications of multiple myeloma: a systematic review and meta-analysis
- 20 September 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (4) , 2125-2136
Prognostic value of MRI-derived features for biochemical recurrence after curative radiotherapy in prostate cancer
Background To evaluate whether pretreatment multiparametric MRI features can predict biochemical recurrence in patients with localized prostate cancer treated with radiation therapy of curative intent. Methods This retrospective single-institution study analyzed patients with prostate cancer who underwent primary radiotherapy between January 2015 and December 2019. All patients underwent pretreatment multiparametric MRI, with or without endorectal coil. Clinical, pathological and MRI features were assessed, with emphasis on qualitative and quantitative imaging characteristics. Univariate binary logistic regression identified significant predictors of recurrence. Variables showing significance (p < 0.05) were included in forward stepwise logistic regression analysis. The primary endpoint was biochemical recurrence, defined by Phoenix criteria. Results The study included 54 patients (mean age 76.57 ± 7.77 years), with 10 patients (18.5%) experiencing biochemical recurrence at a median follow-up of 74.4 months. In univariate analysis, clinical T-stage (OR: 2.24, 95% CI: 1.11–4.56), ISUP grade (OR: 1.86, 95% CI: 1.03–3.37) and NCCN risk groups (OR: 2.55, 95% CI: 1.16–5.62) were significant predictors. Among MRI parameters, total tumor volume (OR: 4.28, 95% CI: 1.59–11.57), extraprostatic extension (OR: 8.57, 95% CI: 1.61–45.73), neurovascular bundle invasion (NBI) (OR: 14.78, 95% CI: 2.97–73.44), and seminal vesicle invasion (OR: 15.00, 95% CI: 2.94–76.56) showed strong associations with recurrence. In stepwise multivariate analysis, NBI emerged as the sole independent predictor (OR: 3.16, 95% CI: 1.59–6.28, p = 0.001), with 86.4% specificity and 92.7% negative predictive value. Conclusion NBI on pretreatment MRI independently predicts biochemical recurrence in patients with localized prostate cancer treated with radiation therapy, highlighting the need to refine risk stratification by incorporating imaging criteria.
- 20 September 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (4) , 2125-2136
Prognostic value of MRI-derived features for biochemical recurrence after curative radiotherapy in prostate cancer
Background To evaluate whether pretreatment multiparametric MRI features can predict biochemical recurrence in patients with localized prostate cancer treated with radiation therapy of curative intent. Methods This retrospective single-institution study analyzed patients with prostate cancer who underwent primary radiotherapy between January 2015 and December 2019. All patients underwent pretreatment multiparametric MRI, with or without endorectal coil. Clinical, pathological and MRI features were assessed, with emphasis on qualitative and quantitative imaging characteristics. Univariate binary logistic regression identified significant predictors of recurrence. Variables showing significance (p < 0.05) were included in forward stepwise logistic regression analysis. The primary endpoint was biochemical recurrence, defined by Phoenix criteria. Results The study included 54 patients (mean age 76.57 ± 7.77 years), with 10 patients (18.5%) experiencing biochemical recurrence at a median follow-up of 74.4 months. In univariate analysis, clinical T-stage (OR: 2.24, 95% CI: 1.11–4.56), ISUP grade (OR: 1.86, 95% CI: 1.03–3.37) and NCCN risk groups (OR: 2.55, 95% CI: 1.16–5.62) were significant predictors. Among MRI parameters, total tumor volume (OR: 4.28, 95% CI: 1.59–11.57), extraprostatic extension (OR: 8.57, 95% CI: 1.61–45.73), neurovascular bundle invasion (NBI) (OR: 14.78, 95% CI: 2.97–73.44), and seminal vesicle invasion (OR: 15.00, 95% CI: 2.94–76.56) showed strong associations with recurrence. In stepwise multivariate analysis, NBI emerged as the sole independent predictor (OR: 3.16, 95% CI: 1.59–6.28, p = 0.001), with 86.4% specificity and 92.7% negative predictive value. Conclusion NBI on pretreatment MRI independently predicts biochemical recurrence in patients with localized prostate cancer treated with radiation therapy, highlighting the need to refine risk stratification by incorporating imaging criteria.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 3: Gating strategy for enrichment of TREM2+SPP1+ macrophages. Labels above the flow plots refer to the parent population in the percentages are of the parent gate.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 3: Gating strategy for enrichment of TREM2+SPP1+ macrophages. Labels above the flow plots refer to the parent population in the percentages are of the parent gate.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Table 1: Metadata for samples involved in this study
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Table 1: Metadata for samples involved in this study
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 6: Spatial architecture of tumor associated macrophages in prostate cancer.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 6: Spatial architecture of tumor associated macrophages in prostate cancer.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Data from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Tumor-associated macrophages (TAM) are a transcriptionally heterogeneous population, and their abundance and function in prostate cancer is poorly defined. We integrated parallel datasets from single-cell RNA sequencing, spatial transcriptomics, and multiplex immunofluorescence to reveal the dynamics of TAMs in primary and metastatic prostate cancer. Four TAM subpopulations were identified. Notably, one of these TAM subsets was defined by the co-expression of SPP1+ and TREM2+ and was significantly enriched in metastatic tumors. The SPP1+/TREM2+ TAMs were enriched in the metastatic tumor microenvironment in both human patient samples and murine models of prostate cancer. The abundance of these SPP1+/TREM2+ macrophages was associated with patient progression-free survival. Spatially, TAMs within prostate cancer bone metastases were highly enriched within the tumor region, consistent with their protumorigenic role. Blocking SPP1 in the RM1 prostate cancer mouse model led to improved efficacy of anti–PD-1 treatment and increased CD8+ T-cell infiltration in tumor. These findings suggest that targeting SPP1+ TAMs may offer a promising therapeutic strategy and potentially enhance the effects of immune checkpoint inhibition in advanced prostate cancer.Implications:This study expands our understanding of the diverse roles of macrophage populations in prostate cancer metastases and highlights new therapeutic targets.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Tumor-associated macrophages (TAM) are a transcriptionally heterogeneous population, and their abundance and function in prostate cancer is poorly defined. We integrated parallel datasets from single-cell RNA sequencing, spatial transcriptomics, and multiplex immunofluorescence to reveal the dynamics of TAMs in primary and metastatic prostate cancer. Four TAM subpopulations were identified. Notably, one of these TAM subsets was defined by the co-expression of SPP1+ and TREM2+ and was significantly enriched in metastatic tumors. The SPP1+/TREM2+ TAMs were enriched in the metastatic tumor microenvironment in both human patient samples and murine models of prostate cancer. The abundance of these SPP1+/TREM2+ macrophages was associated with patient progression-free survival. Spatially, TAMs within prostate cancer bone metastases were highly enriched within the tumor region, consistent with their protumorigenic role. Blocking SPP1 in the RM1 prostate cancer mouse model led to improved efficacy of anti–PD-1 treatment and increased CD8+ T-cell infiltration in tumor. These findings suggest that targeting SPP1+ TAMs may offer a promising therapeutic strategy and potentially enhance the effects of immune checkpoint inhibition in advanced prostate cancer.Implications:This study expands our understanding of the diverse roles of macrophage populations in prostate cancer metastases and highlights new therapeutic targets.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Table S4 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Table 4: Nano-string DSP spatial expression of proteins
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Table 4: Nano-string DSP spatial expression of proteins
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 2: Heterogeneity of tumor associated macrophage localized prostate cancer.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 2: Heterogeneity of tumor associated macrophage localized prostate cancer.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 1: Immune cell infiltration in localized prostate cancer.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 1: Immune cell infiltration in localized prostate cancer.
- Open Access
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 4: A-B. Boxplot showing macrophage marker gene expression in TCGA (A) and GSE21034 (B) prostate cancer bulk RNAseq datasets.
- 2 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Single-Cell and Spatial Transcriptomics Reveal a Tumor-Associated Macrophage Subpopulation that Mediates Prostate Cancer Progression and Metastasis
Supplementary Figure 4: A-B. Boxplot showing macrophage marker gene expression in TCGA (A) and GSE21034 (B) prostate cancer bulk RNAseq datasets.